Best Cell Therapy CDMOs in Asia
· updated as new inspection, certificate, and trial data enters the platform
15
CDMOs tracked
15
Fully scored
6
With FDA records
21
FDA inspections
42
EMA/MHRA GMP certs
6
Warning letters
Cell therapy CDMOs manufacture living products — CAR-T, TCR, NK, and stem-cell therapies — where the process is the product. Autologous programs add patient-scheduling and chain-of-identity demands that allogeneic, batch-based programs avoid.
The right cell therapy CDMO depends on autologous vs allogeneic experience, vector sourcing, closed-system processing, and cold-chain logistics. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 8 NAI (no action), 10 VAI (voluntary action), 3 OAI (official action). Leading inspection & GMP sites: Denmark (23), India (13), United States (6), Germany (6), INDIA (5).
Last updated 2026-10-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 35 open roles
|
78.5 | 99.8 | 4 insp · 27 GMP | Available | 2 programs |
| 2 |
MN
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
|
83.0 | 99.1 | 3 insp · 4 GMP | Limited | 0 programs |
| 3 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
82.7 | 99.6 | 1 insp · 4 GMP | — | 0 programs |
| 4 |
SG
Syngene International
Bengaluru, India
Hiring · 6 open roles
|
80.3 | 100.0 | 3 insp · 0 GMP | — | 0 programs |
| 5 |
BC
Biocon Biologics
Bengaluru, India
Hiring · 65 open roles
|
75.7 | 93.0 | 7 insp · 2 GMP | — | 0 programs |
| 6 |
GenScript
Piscataway, NJ / Nanjing, China
|
64.0 | — | — | — | 0 programs |
| 7 |
PBI
ProBio
Pennington, NJ · Nanjing, CN
|
64.0 | — | — | — | 0 programs |
| 8 |
HG
Hitachi Global Life Solutions (CGT)
Yokohama, Japan
|
63.0 | — | — | — | 0 programs |
| 9 |
SM
Sumitomo Chemical Advanced Medical
Tokyo, JP
|
63.0 | — | — | — | 0 programs |
| 10 |
EA
Esco Aster
Singapore, Singapore
|
63.0 | — | — | — | 0 programs |
| 11 |
CTP
Cell Therapies Pty Ltd
Melbourne, Australia
|
59.0 | — | — | — | 0 programs |
| 12 |
SS
Singota Solutions
Bloomington, IN
|
59.0 | — | — | — | 0 programs |
| 13 |
GC
Green Cross Cell
Yongin, KR
|
56.5 | — | — | — | 0 programs |
| 14 |
CH
CHA Medical & Bio Group
Seongnam, KR
|
56.5 | — | — | — | 0 programs |
| 15 |
IP
Intas Pharmaceuticals
Ahmedabad, India
|
46.8 | 35.7 | 3 insp · 5 GMP | — | 0 programs |
What to evaluate in a Cell Therapy CDMO
Autologous vs allogeneic
Autologous needs per-patient scheduling, chain-of-identity, and short turnaround; allogeneic needs scalable batch processing and a master cell bank strategy. Pick a CDMO proven in your model.
Vector & raw materials
Most cell therapies need a viral vector. Confirm whether the CDMO makes vector in-house or coordinates an external supplier, and how that affects timelines.
Closed-system & cleanrooms
Closed, automated processing reduces contamination risk and labor. Ask about cleanroom grade, automation platforms, and parallel-suite capacity.
Cold chain & logistics
Cryopreservation and chain-of-custody are critical for living cells. Evaluate the CDMO's cold-chain and apheresis-to-infusion logistics.
Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)
Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.
Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?
Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.
Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)
Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.
Cell Therapy CDMOs — Frequently Asked Questions
Who are the top Cell Therapy CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Cell Therapy CDMOs include AGC Biologics, Minaris Advanced Therapies, WuXi Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Cell Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 6 Cell Therapy CDMOs with FDA inspection records and 42 EMA/MHRA GMP certificates across the group.
What should I look for in a cell therapy CDMO?
Match the CDMO to your model: autologous needs chain-of-identity and fast turnaround; allogeneic needs scalable batch processing. Confirm vector sourcing, closed-system processing, cold-chain logistics, and a clean FDA and EMA/MHRA record.
Do cell therapy CDMOs make their own viral vectors?
Some do in-house; others coordinate an external vector supplier. In-house vector can shorten timelines and simplify supply, but a strong external partner is common. Check each profile's modality coverage above.
Related modalities